3Duman RS,Aghajanian GK.Synaptic dysfunction in depres- sion:potential therapeutic targets[J].Science,2012,338(613):68-72.
4Diazgranados N,Ibrahim L,Brutsche NE,et al.A randomized add-on trial of an N-methyl-D-aspartate antagonist in treat- ment-resistant bipolar depression[J].Arch Gen Psychiatry,2010,67(8):793-802.
5Berman RM,Cappiello A,Anand A,et al.Antidepressant effects of ketamine in depressed patients[J].Biol Psychia- try,2000,47(4):351-354.
6Wang X,Chen Y,Zhou X,et al.Effects of propofol and ket- amine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder[J].J ECT,2012,28(2):128-132.
7Tavoli A, Mohagheghi MA, Montazeri A, et al. Anxiety and depression in patients with gastrointestinal cancer: does knowledge of diagnosis matter. BMC Gastroenterol, 2007,14.. 7-28.
8Lapidus KA, Leviteh CF, Perez AM, et al. A randomized con trlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry, 2014, 76(12)..970 976.
9Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse forma- tion underlies the rapid antidepressant effects of NMDA An- tagonists.Science, 2010,329 (5994) .. 959-964.
10Murrough JW,Perez AM. Antidepressant efficacy of ketarnine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry, 2013, 170(10): 1134-1142.
